.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 5,856,346

« Back to Dashboard

Claims for Patent: 5,856,346

Title: Short-acting dihydropyridines
Abstract:Compounds of the general formula ##STR1## wherein R.sub.1 and R.sub.2 are independently selected from the group consisting of hydrogen, chloro, bromo, nitro, cyano, trifluoromethyl, and R.sub.3 and R.sub.4 are independently selected from straight or branched lower (1-5 carbon atoms) alkyl groups, and including all optical isomers, provided that when R.sub.3 is methyl and R.sub.4 is tert.-butyl, then R.sub.1 /R.sub.2 are not hydrogen/hydrogen, hydrogen/2'-trifluormethyl, 2'-chloro/3'-chloro, and when R.sub.3 is methyl and R.sub.1 /R.sub.2 is hydrogen/3'-nitro, then R.sub.4 are not methyl, ethyl, propyl, iso-propyl, tert.-butyl, processes for their preparation, pharmaceutical preparations containing them and the use of the compounds in lowering the blood pressure.
Inventor(s): Andersson; Kjell Hjalmar (Fjar.ang.s, SE), Nordlander; Margareta (Askim, SE), Westerlund; Rolf Christer (Molndal, SE)
Assignee: Astra Aktiebolag (Sodertalje, SE)
Application Number:08/356,224
Patent Claims: 1. A compound of the formula ##STR12## wherein R.sub.1 and R.sub.2 are independently selected from the group consisting of hydrogen, chloro, bromo, nitro, cyano and trifluoromethyl, and R.sub.3 and R.sub.4 are independently selected from the group consisting of straight and branched C.sub.1-5 alkyl groups and including all optical isomers, provided that when R.sub.3 is methyl and R.sub.4 is tert-butyl, then R.sub.1 /R.sub.2 are not hydrogen/hydrogen, hydrogen/ 2'-trifluoromethyl, 2'-chloro/3'-chloro, and when R.sub.3 is methyl and R.sub.2 /R.sub.1 is hydrogen/3'-nitro, then R.sub.4 is not methyl, ethyl, propyl, iso-propyl or tert-butyl or a pharmaceutically acceptable salt thereof.

2. A compound according to claim 1, selected from

1) Butyroxymethyl methyl 4-(2'3'-dichlorophenyl)2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate

2)(4S)-Butyroxymethyl methyl 4-(2',3'-dichlorophenyl)2,6-dimethyl-1,4-dihydropyridi ne-3 ,5-dicarboxylate

3) (4R)-Butyroxymethyl methyl 4-(2',3'-dichlorophenyl)2,6-dimethyl-1,4-dihydropyridi ne-3 ,5-dicarboxylate

4) iso-Butyroxymathyl methyl 4-(2',3'-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylat e.

3. A process for the preparation of a compound of the formula I as defined in claim 1, wherein

a) alkylation of a compound of the formula 11 ##STR13## with a compound of the formula

in which formulas R.sub.1 -R.sub.4 are defined in claim 1 and X is a standard leaving group, or

b) condensation of a compound of the formula III ##STR14## with an aminocrotonate of the formula IV ##STR15## in which formulas R.sub.1 -R.sub.4 are as defined in claim 1, or c) condensation of a compound of the formula V ##STR16## with an aminocrotonate of the formula VI ##STR17## in which formulas R.sub.1 -R.sub.4 are defined in claim 1 or d) reaction of a benzaldehyde of the formula VIII ##STR18## with a acetoacetate of the formula VII ##STR19## and an aminocrotonate of the formula VI ##STR20## in which formulas R.sub.1 -R.sub.4 are as defined in claim 1, or e) reaction of a benzaldehyde of the formula VIII ##STR21## with an acetoacetate of the formula IX ##STR22## and an aminocrotonate of the formula IV ##STR23## in which formulas R.sub.1 -R.sub.4 are as defined in claim 1, or f) reaction of a benzylidene compound of the general formula III ##STR24## with an acetoacetate of the general formula VII ##STR25## in the presence of ammonia, in which formulas R.sub.1 -R.sub.4 are as defined in claim 1, or

g) reaction of a benzylidene compound of the general formula V ##STR26## with an acetoacetate of the formula IX ##STR27## in the presence of ammonia, in which formulas R.sub.1 -R.sub.4 are as defined in claim 1, or

h) reaction of acetoacetates of the general formulas VII and IX ##STR28## ##STR29## with a benzaldehyde of the general formula VIII ##STR30## in the presence of ammonia, in which formulas R.sub.1 -R.sub.4 are as defined in claim 1, alternatively wherein the compound obtained by any of the processes a)-h) is converted to an optical isomer thereof by known methods.

4. A process according to claim 3, wherein a compound according to claim 2 is prepared.

5. A pharmaceutical composition comprising an effective amount of a compound according to claim 1 or 2.

6. A pharmaceutical composition according to claim 5 in dosage unit form.

7. A pharmaceutical composition according claim 5 comprising a compound according to claim 1 or 2 in association with a pharmaceutically acceptable carrier.

8. A method for lowering the blood pressure in a host comprising administering to a host in need of such treatment an effective amount of a compound according to claim 1 or 2.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc